Ashling Wahner

Associate Editor, OncLive

Ashling Wahner joined MJH Life Sciences in 2022. She produces OncLive's podcast, OncLive On Air, and helps ensure timely publication of news content and announcements from the FDA approval pipeline. She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: awahner@mjhlifesciences.com

Articles

Donor Clonal Hematopoiesis May Predict Post-Transplant Relapse and Outcomes in Hematologic Malignancies

October 16th 2024

Screening for donor-derived clonal hematopoiesis may have prognostic value for outcomes following auto-HSCT in patients with hematologic malignancies.

Venetoclax/Rituximab Retreatment Produces Durable Responses in CLL

October 16th 2024

Retreatment with venetoclax plus rituximab generated responses in patients with CLL who had responded to and progressed after initial venetoclax treatment.

Dr Klisovic on a Case Discussion of Momelotinib in Myelofibrosis With Anemia

October 16th 2024

Rebecca Klisovic, MD, discusses 3 case studies about patients with myelofibrosis.

ADCs Usher in a Complex New Era of Disease and Toxicity Management in Bladder Cancer

October 15th 2024

Jacqueline Brown, MD, discusses the nuanced potential role of immunotherapy-ADC and dual-ADC combinations in bladder cancer.

FDA Grants Orphan Drug Designation to IMM-1-104 for Pancreatic Cancer

October 15th 2024

The FDA has granted orphan drug designation to IMM-1-104 for pancreatic cancer.

FDA Grants Fast Track Designation to LP-184 for Glioblastoma

October 15th 2024

LP-184 has received fast track designation from the FDA for the treatment of patients with glioblastoma.

Toripalimab Wins Approval in India and Hong Kong for Recurrent/Metastatic Nasopharyngeal Carcinoma

October 15th 2024

Toripalimab has been approved in India and China’s Hong Kong Special Administrative Region for recurrent or metastatic nasopharyngeal carcinoma.

Lurbinectedin/Atezolizumab Combination Improves Survival in ES-SCLC

October 15th 2024

Lurbinectedin plus atezolizumab produced significant OS and PFS benefits as frontline maintenance for extensive-stage small cell lung cancer.

Increased ctDNA and MMR Testing May Alter Adjuvant and Neoadjuvant CRC Management

October 15th 2024

Benjamin Adam Weinberg, MD, discusses the prognostic value of adjuvant ctDNA testing in CRC and the role of immune checkpoint inhibition in dMMR CRC.

Navigating Myelofibrosis: Updates for Community Hematologist Oncologists

October 14th 2024

Drs Gerds and McCloskey discuss JAK inhibitors for patients with myelofibrosis, tips for symptom management, and emerging myelofibrosis research.

Dr Weinberg on the Prognostic Use of ctDNA Testing in Resected CRC

October 14th 2024

Benjamin Adam Weinberg, MD, discusses the ability of ctDNA-based MRD detection to predict the benefit of adjuvant chemotherapy in resected CRC.

Fixed-Duration Ibrutinib/Venetoclax Elicits Meaningful Survival Benefit in High-Risk CLL/SLL

October 12th 2024

Fixed-duration ibrutinib plus venetoclax generated meaningful survival benefits and durable responses in high-risk subgroups of patients with CLL/SLL.

Dr Krishnan on the Optimal Use of DKd in Relapsed/Refractory Multiple Myeloma

October 11th 2024

Amrita Krishnan, MD, discusses the role of DKd for patients with relapsed/refractory multiple myeloma.

Dr Hernandez-Ilizaliturri on Selecting Between CAR T-Cell Therapies for FL

October 11th 2024

Francisco Hernandez-Ilizaliturri, MD, discusses factors that inform the selection of CAR T-cell therapies for patients with follicular lymphoma.

Cisplatin’s Prevalence in Bladder Cancer Falters With the Introduction of Enfortumab Vedotin

October 11th 2024

Jacqueline Brown, MD, explains the need to determine optimal second-line bladder cancer treatments for use after enfortumab vedotin/pembrolizumab.

VIP943 Generates Early Complete Responses, Is Safe in Advanced CD123+ Hematologic Malignancies

October 11th 2024

Complete responses were achieved by 2 patients with advanced CD123-positive hematologic malignancies who received VIP943 in a phase 1 study.

Enfortumab Vedotin Plus Pembrolizumab Stands Strong as the Frontline Bladder Cancer SOC

October 10th 2024

Jacqueline Brown, MD, discusses the current role of enfortumab vedotin plus pembrolizumab in bladder cancer and tips for early AE management.

FDA Approval Insights: Vorasidenib in IDH1/2+ Grade 2 Astrocytoma and Oligodendroglioma

October 10th 2024

Dr Taylor discusses the significance of the FDA approval of vorasidenib for patients with IDH-positive grade 2 astrocytoma or oligodendroglioma.

2023 Chemotherapy Shortages Drove Altered Treatment Plans, Persistent Cost Increases

October 9th 2024

The 2023 cisplatin shortage led to shifts toward the use of alternative agents for use in head and neck cancer, as well as increased drug costs.

Myelofibrosis Treatment Advances Rely on Past Developments to Drive Future Innovation

October 9th 2024

Idoroenyi Amanam, MD, discusses JAK inhibitor–associated AE management and considerations for the future use of stem cell transplant in myelofibrosis.